Genmab stock
Price history
+80.66% over the period1 year: from kr 1,975.50 (November 17, 2025) to kr 3,569.00 (November 16, 2026), +80.66%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | kr 3,569.00 |
| October 30, 2026 | kr 3,912.00 |
| September 30, 2026 | kr 2,343.00 |
| August 31, 2026 | kr 2,122.00 |
| July 31, 2026 | kr 1,858.50 |
| June 30, 2026 | kr 1,795.00 |
| May 29, 2026 | kr 1,704.00 |
| April 30, 2026 | kr 1,690.00 |
| March 31, 2026 | kr 1,713.00 |
| February 27, 2026 | kr 1,848.50 |
| January 30, 2026 | kr 2,022.00 |
| December 30, 2025 | kr 2,027.00 |
| November 28, 2025 | kr 2,039.00 |
| November 17, 2025 | kr 1,975.50 |
At a glance
The company
Develops antibody-based products for treating cancer and other diseases, with marketed therapies for lymphomas, cervical cancer and multiple myeloma, plus an extensive pipeline
Latest results
Quarter to September 30, 2026 · EPS $37.53 (estimate $22.99)
TickerLandia's take on Genmab
- Pricier than similar companies: trailing 12-month P/E 47 vs 40 (+16%) in a group of 10.
- Strong point: Market momentum (98/100 in its group). Weak point: Financial strength (28/100).
- “Most upside for analysts” (Denmark): No. 7 of 21.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.59% from the 52-week high
Analysts · 16 analysts
Average targetkr 4,056.77+14.96% vs. price
Buy 14 · Hold 2 · Sell 0 · Strong buy
TickerLandia Fingerprint: Genmab
Compared with similar companies: very strong momentum, very high earnings stability, and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh69
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 45.8 63 Forward P/E 29.5 54 Price/book 5.18 47 EV/EBITDA 163.4 93 Price/sales 49.5 87 Profitabilityhigh66
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 30.6% 73 ROE 12.1% 53 Gross margin 92.7% 80 ROA 8.2% 66 Net margin 17.0% 57 Earnings stabilityvery high86
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.5% 89 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage44
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +21.23% 46 Revenue growth (year over year) +16.10% 39 Earnings growth (year over year) −14.70% 46 Financial strengthlow28
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.82 13 Interest coverage 20.5 60 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.88 7 Current ratio 2.45 34 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong98
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +75.52% 96 Distance from 200-day average +68.34% 100 Riskvery high86
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 32.3% 74 Volatility (60 days) 66.0% 97
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Genmab is pricier than similar companies
Genmab's P/E (trailing 12 months): 47.0, +16% against the median of a group of 10 similar companies (40.4).
Compared with 10 similar companies
| Metric | Genmab | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 47.0 | Middle | |
| Forward P/E | 30.2 | Middle | |
| Operating margin | 30.6% | Middle | |
| ROE | 12.1% | Middle | |
| Debt/equity | 0.82 | High |
Grey band: the middle half of the group; tick: the median; dot: Genmab. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.19B
Latest quarter · Q3 2026
Net income
$342M
Latest quarter · Q3 2026
Quarterly net margin
28.8%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- kr 217.84B
- P/E
- 47.0
- EPS
- kr 75.25
- Volume
- 20.01K
- Daily trading
- €111.03M
- Dividend yield
- 0.00%
How Genmab is changing
All resultsRevenue grew 17.5% a year on average over the last 5 years
Operating margin fell from 43.2% to 33.6%
Profits turn into cash: free cash flow equal to 120% of net income
Returns
Genmab returns
kr 1,000 invested in Genmab 5 years ago, on November 16, 2021, would be worth kr 1,316 today: +31.55% in total, +5.64% per year. This is the price return only: dividends are excluded.
| Period | Genmab | kr 1,000 becomes |
|---|---|---|
| 1 month | +42.65% | kr 1,426 |
| 6 months | +109.56% | kr 2,096 |
| Year to date | +76.07% | kr 1,761 |
| 1 year | +80.66% | kr 1,807 |
| 3 years | +62.52% | kr 1,625 |
| 5 years | +31.55% | kr 1,316 |
| 10 years | +190.40% | kr 2,904 |
Price only, without dividends. Calculate your investment
The chart in detail
Genmab: technical analysis
Genmab is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 9.8% below its all-time closing high (kr 3,912.00, October 30, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- +71.67%
Support and resistance
Price areas where Genmab has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last pricekr 3,529.00
- Supportkr 2,216.80−37.18%5 touches, last on October 2, 2026
- Supportkr 2,081.00−41.03%3 touches, last on September 11, 2026
- Supportkr 1,942.44−44.96%8 touches, last on July 28, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 65.8%
- Largest fall in the last year
- −32.30%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Genmab: seasonality
Average monthly price change over 26 years
Over the last 26 years, the strongest month for Genmab has been January: +6.90% on average, positive in 15 years out of 26. The weakest has been June: −1.90% on average, positive in 11 years out of 26. November, the current month, has been positive in 12 years out of 26 (−0.18% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +6.90% | +4.36% | 15 of 26 |
| February | −0.58% | −1.35% | 10 of 26 |
| March | +0.41% | +0.41% | 13 of 26 |
| April | +2.61% | +2.40% | 16 of 26 |
| May | +3.46% | −0.38% | 12 of 26 |
| June | −1.90% | −3.45% | 11 of 26 |
| July | +6.56% | +4.99% | 17 of 26 |
| August | +0.26% | −0.31% | 13 of 26 |
| September | −1.23% | −0.97% | 13 of 26 |
| October | +3.39% | +2.00% | 14 of 26 |
| November | −0.18% | −0.85% | 12 of 26 |
| December | +3.94% | +1.63% | 14 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Genmab and its competitors
Founded in 1998 and based in Copenhagen, Denmark, Genmab works on antibody-based medicines for cancer and other diseases. Its marketed products include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, Tivdak for recurrent or metastatic cervical cancer, and DARZALEX and DARZALEX FASPRO for multiple myeloma, and it has collaboration agreements with companies including AbbVie, Pfizer and Johnson & Johnson.
- Headquarters
- Copenhagen, Denmark
- Employees
- 3,244
- Founded
- 1998
- Chief executive
- Jan G.J. de Winkel
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| GenmabGMAB | $32.21B | 30.6% | 47.0 | +109.56% |
| UCBUCB | $62.44B | 29.5% | 26.2 | +24.51% |
| Financière de TubizeTUB | $11.2B | -42,153.6% | 102.5 | +21.43% |
| ALK-AbellóALK.B | $8.14B | 26.9% | 40.7 | +0.16% |
| ABIVAXABVX | $7.65B | -6,270.4% | — | −22.36% |
| Bachem HoldingBANB | $7.43B | 21.8% | 41.9 | +5.24% |
Same industry or related industries, similar size. Compare Genmab with its competitors · Full profile
